Deep Breath: Optimizing Selection and Use of Medication Devices in COPD

Kyle Copeland, PharmD
Published Online: Monday, July 23, 2012
Follow Pharmacy_Times:
Deep Breath: Optimizing Selection and Use of Medication Devices in COPD
 
Kyle Copeland, PharmD

Clinical Pharmacist Specialist
Parkwest Medical Center
Knoxville, Tennessee

 

 
Kyle Copeland, PharmD, has no relevant affiliations or financial relationships with commercial interests to disclose related to this activity.
 
Pharmacy Times Office of Continuing Professional Education Planning Staff
 
Judy V. Lum, MPA, Ann C. Lichti, CCMEP, and Elena Beyzarov, PharmD, have no relevant affiliations or financial relationships with commercial interests to disclose related to this activity.
 
Pharmacy Times Editorial

Jennifer Whartenby and David Allikas have no relevant affiliations or financial relationships with commercial interests to disclose related to this activity.
 

 
Educational Objectives
 
Upon completion of this educational activity, participants should be able to:
  1. Examine current prevalence, diagnosis, and treatment of COPD.
  2. Apply current guideline recommendations to improve standards of care and patient outcomes.
  3. Explore a patient-specific approach to managing difficult-to-treat patients with COPD.
  4. Discuss proper selection and use of currently available medication devices for COPD.
Target audience: Pharmacists
Type of activity: Knowledge
Release date: July 4, 2012
Expiration date: July 4, 2014
Estimated time to complete activity: 2 hours
Fee: This lesson is free online.
 
Click here to view this activity.

Related Articles
Novartis announced that it has submitted New Drug Applications to the FDA for QVA149 and NVA237, investigational drugs for the long-term maintenance treatment of chronic obstructive pulmonary disease, following positive results from phase 3 trials of the drugs.
Rhinovirus infection tends to aggravate other conditions in the elderly.
Tiotropium, a once-daily inhaled long-acting anticholinergic bronchodilator, provides airflow improvement for at least 24 hours in chronic obstructive pulmonary disease patients. Its use has been linked to fewer exacerbations, less dyspnea, and improved quality of life.
Patients with bronchial asthma or chronic obstructive pulmonary disease fare best with metered dose inhalers that have spacer devices.
Latest Issues
  • photo
    Pharmacy Times
    photo
    Health-System Edition
    photo
    Directions in Pharmacy
    photo
    OTC Guide
    photo
    Generic Supplements
  • photo
    Pharmacy Careers
    photo
    Specialty Pharmacy Times
    photo
    Generic
$auto_registration$